The global osteoporosis market is expected to witness patient number growth in the coming years, aided by an increasingly ageing population, which in turn increases the incidence of osteoporosis. However, growth in the number of patients is not expected to lead to growth in the overall value of the global osteoporosis market. This is due to the genericization of key bisphosphonate brands, which will cause price erosion, and lead to the industry actually witnessing a decline in growth between 2013 and 2021.
The growth in sales of newer products, such as Prolia (denosumab; Amgen) and soon-to-launch odanacatib (Merck & Co.) can only partly offset the market value decline caused by generic price erosion. Odanacatib will become the top-grossing pipeline drug by the end of the forecast period.For more information on the Global osteoporosis market, please click here: Global osteoporosis market
Companiesandmarkets.com issues news updates and report summaries covering all major industries and sectors. The service provides additional client monitoring and timely alerts to breaking industry and sector news leading the day's business headlines. News articles, written by our staff, contain additional analyst insight, providing value added insight for our readers. News updates and real-time alerts on newly-released market reports are also available from our Facebook page, Twitter feed @CandMResearch and RSS links. We also welcome inquiries from business journalists and the news media.